Vividion Therapeutics

Vividion Therapeutics is a private, clinical-stage biotech pioneering a novel drug discovery engine that merges chemoproteomics and covalent chemistry to drug challenging disease targets. The company has advanced multiple programs into clinical trials, including a WRN helicase inhibitor for MSI-high cancers and a KEAP1 activator in oncology, demonstrating platform validation. Led by CEO Aleksandra Rizo, M.D., Ph.D., and CSO Matt Patricelli, Ph.D., Vividion is positioned to address the vast unmet need represented by the estimated 90% of disease-causing proteins currently considered undruggable. Its success hinges on translating its unique platform into clinically effective and commercially viable precision medicines.

Proprietary chemoproteomics platform integrated with covalent chemistry expertise to screen the native human proteome and identify novel, druggable binding sites on proteins considered undruggable by conventional methods.

Vividion competes with other biotechs employing chemoproteomics (e.g., Frontier Medicines, Matchpoint Therapeutics) and covalent drug discovery platforms. Its differentiation lies in the specific integration of its screening technology and chemistry expertise. It also competes broadly with all companies pursuing novel oncology targets, including those using modalities like protein degradation.